Assembly Biosciences, Inc.
ASMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 298.2% | – | -100% | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 100% | -582.7% | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -158.8% | -896.2% | – | -1,448.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -140.9% | -854.8% | – | -2,076.4% |
| EPS Diluted | -6.69 | -13.38 | -22.82 | -36 |
| % Growth | 50% | 41.4% | 36.6% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |